Shares of Regulus Therapeutics (NASDAQ:RGLS) spiked on Thursday after the microRNA-focused drug developer announced additional topline data from a Phase 1b trial for its lead asset, farabursen, ...

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative ...

He had a younger brother called Regulus Black, who became an unlikely crusader against the Dark Lord. Regulus Had Pure-Blood Notions Like His Family Unlike Sirius, Regulus subscribed to the pure ...

Also Read: Why Is Kidney Disease-Focused Regulus Therapeutics Stock Trading Higher On Tuesday? The full cohort of 26 patients demonstrated a similar mechanistic response based on urinary PC1 and ...

Regulus (RGLS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the ...

In December 2024, Regulus met with the FDA for an End-of-Phase 1 meeting where they reached alignment on the acceptability of the program's CMC, non-clinical and clinical pharmacology plans and ...

Buoyed by encouraging data for its lead drug for autosomal dominant polycystic kidney disease, Regulus Therapeutics has moved swiftly to file a financing that will give it the finances needed to ...

Wells Fargo upgraded Regulus (RGLS) to Overweight from Equal Weight with a price target of $6, up from $3.Light Up your Portfolio with ...

Oppenheimer analyst Andreas Argyrides maintained a Buy rating on Regulus (RGLS – Research Report) today and set a price target of $7.00. The ...

Explore Regulus Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for RGLS. Regulus Therapeutics Stock Shoots Higher After Positive Results From ...

Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...